Overview

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
interventional trial for off label use of high dose atorvastatin 80 mg in intermediate AMD patients and correlate recovery response measured by dark adaptation recovery time with drusen volume reduction measured by SD-OCT
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts Eye and Ear Infirmary
Treatments:
Atorvastatin